WO2007132120A3 - Procede et methodes de detection de la maladie d'alzheimer - Google Patents

Procede et methodes de detection de la maladie d'alzheimer Download PDF

Info

Publication number
WO2007132120A3
WO2007132120A3 PCT/FR2007/051263 FR2007051263W WO2007132120A3 WO 2007132120 A3 WO2007132120 A3 WO 2007132120A3 FR 2007051263 W FR2007051263 W FR 2007051263W WO 2007132120 A3 WO2007132120 A3 WO 2007132120A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
alzheimer
methods
procedure
mammals
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2007/051263
Other languages
English (en)
Other versions
WO2007132120A2 (fr
Inventor
Fabien Schweighoffer
Laurent Bracco
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/227,374 priority Critical patent/US20100055682A1/en
Priority to AU2007251408A priority patent/AU2007251408B2/en
Priority to NZ573505A priority patent/NZ573505A/en
Priority to EP07766039A priority patent/EP2021509A2/fr
Priority to CN2007800267862A priority patent/CN101490280B/zh
Priority to CA002652258A priority patent/CA2652258A1/fr
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Priority to JP2009510510A priority patent/JP2009537133A/ja
Publication of WO2007132120A2 publication Critical patent/WO2007132120A2/fr
Publication of WO2007132120A3 publication Critical patent/WO2007132120A3/fr
Priority to IL195288A priority patent/IL195288A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente demande concerne des méthodes et compositions utilisables pour la détection de la maladie d'Alzheimer chez les mammifères, en particulier les humains. Elle décrit notamment des marqueurs sériques de la maladie d'Alzheimer et leurs utilisations dans des méthodes de diagnostic. Elle concerne également des outils et/ou kits utilisables pour la mise en oeuvre de ces méthodes (réactifs, sondes, amorces, anticorps, puces, cellules, etc.), leur préparation et leurs utilisations. L'invention est utilisable pour détecter la présence ou l'évolution de la maladie d'Alzheimer chez les mammifères, y compris en phase précoce.
PCT/FR2007/051263 2006-05-15 2007-05-14 Procede et methodes de detection de la maladie d'alzheimer Ceased WO2007132120A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2007251408A AU2007251408B2 (en) 2006-05-15 2007-05-14 Procedure and methods for detecting Alzheimer's disease
NZ573505A NZ573505A (en) 2006-05-15 2007-05-14 Procedure and methods for detecting alzheimer's disease
EP07766039A EP2021509A2 (fr) 2006-05-15 2007-05-14 Procédé et méthodes de détection de la maladie d'alzheimer
CN2007800267862A CN101490280B (zh) 2006-05-15 2007-05-14 检测阿尔茨海默病的试剂
CA002652258A CA2652258A1 (fr) 2006-05-15 2007-05-14 Procede et methodes de detection de la maladie d'alzheimer
US12/227,374 US20100055682A1 (en) 2006-05-15 2007-05-14 Procedure and methods for detecting alzheimers's disease
JP2009510510A JP2009537133A (ja) 2006-05-15 2007-05-14 アルツハイマー病を検出するための手順および方法
IL195288A IL195288A (en) 2006-05-15 2008-11-13 Methods for identifying Alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0604294A FR2900936B1 (fr) 2006-05-15 2006-05-15 Procede et methodes de detection de la maladie d'alzheimer
FR0604294 2006-05-15

Publications (2)

Publication Number Publication Date
WO2007132120A2 WO2007132120A2 (fr) 2007-11-22
WO2007132120A3 true WO2007132120A3 (fr) 2008-05-08

Family

ID=37496633

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/051263 Ceased WO2007132120A2 (fr) 2006-05-15 2007-05-14 Procede et methodes de detection de la maladie d'alzheimer

Country Status (12)

Country Link
US (1) US20100055682A1 (fr)
EP (1) EP2021509A2 (fr)
JP (1) JP2009537133A (fr)
KR (1) KR20090098941A (fr)
CN (1) CN101490280B (fr)
AU (1) AU2007251408B2 (fr)
CA (1) CA2652258A1 (fr)
FR (2) FR2900936B1 (fr)
IL (1) IL195288A (fr)
NZ (1) NZ573505A (fr)
WO (1) WO2007132120A2 (fr)
ZA (1) ZA200810528B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2929292A1 (fr) * 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
JP5435587B2 (ja) * 2008-05-23 2014-03-05 持田製薬株式会社 食細胞の機能評価方法
US20100099609A1 (en) * 2008-07-28 2010-04-22 Buck Institute For Age Research eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE
KR101295019B1 (ko) * 2011-04-22 2013-08-09 경북대학교 산학협력단 리포칼린 2 수준을 측정하는 것을 포함하는 경도 인지 장애 진단용 조성물, 키트 및 경도인지 장애 진단을 위한 정보 제공방법.
US9541561B2 (en) 2012-06-14 2017-01-10 Electronics And Telecommunications Research Institute Method for diagnosing Alzheimer's disease using biomaterial
EP2728015A1 (fr) * 2012-10-31 2014-05-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédé pour le diagnostic du syndrome de Sézary
WO2016024101A1 (fr) * 2014-08-13 2016-02-18 Timmons James Archibald Diagnostic médical
CN104328200B (zh) * 2014-11-18 2016-04-06 宁波大学 辅助诊断阿尔茨海默病的检测试剂盒及其检测方法
US20200199645A1 (en) * 2017-09-08 2020-06-25 Control Of Innate Immunity Technology Research Association Device and method for diagnosis of alzheimer's symptoms
EP4376824A4 (fr) * 2021-07-27 2025-05-07 The Hong Kong University of Science and Technology Compositions et méthodes de traitement de la maladie d'alzheimer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0791660A1 (fr) * 1996-02-22 1997-08-27 Smithkline Beecham Corporation Nouveau marqueur diagnostique pour variations d'épissage de gènes en association avec fonctions neurologiques
WO2002008449A2 (fr) * 2000-07-25 2002-01-31 The Sir Mortimer B. Davis - Jewish General Hospital Suppresseur de ho-1 utile comme test de diagnostic et de pronostic dans les maladies dementielles
EP1479396A1 (fr) * 2002-01-31 2004-11-24 Celestar Lexico-Sciences, Inc. Medicaments ameliorant les troubles du rythme circadien
EP1491213A1 (fr) * 2002-03-29 2004-12-29 Celestar Lexico-Sciences, Inc. Inhibiteurs de phosphorylation c-jun

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
GB0227238D0 (en) * 2002-11-21 2002-12-31 Diagenic As Product and method

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0791660A1 (fr) * 1996-02-22 1997-08-27 Smithkline Beecham Corporation Nouveau marqueur diagnostique pour variations d'épissage de gènes en association avec fonctions neurologiques
WO2002008449A2 (fr) * 2000-07-25 2002-01-31 The Sir Mortimer B. Davis - Jewish General Hospital Suppresseur de ho-1 utile comme test de diagnostic et de pronostic dans les maladies dementielles
EP1479396A1 (fr) * 2002-01-31 2004-11-24 Celestar Lexico-Sciences, Inc. Medicaments ameliorant les troubles du rythme circadien
EP1491213A1 (fr) * 2002-03-29 2004-12-29 Celestar Lexico-Sciences, Inc. Inhibiteurs de phosphorylation c-jun

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CARDINALI DANIEL P ET AL: "Clinical perspectives for the use of melatonin as a chronobiotic and cytoprotective agent.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES DEC 2005, vol. 1057, December 2005 (2005-12-01), pages 327 - 336, XP002460021, ISSN: 0077-8923 *
DATABASE GEO 11 March 2002 (2002-03-11), "Affymetrix GeneChip Human Genome U133 Array Set HG-U133A", XP002411782, retrieved from NCBI Database accession no. GPL96 *
LIU R-Y ET AL: "DECREASED VASOPRESSIN GENE EXPRESSION IN THE BIOLOGICAL CLOCK OF ALZHEIMER DISEASE PATIENTS WITH AND WITHOUT DEPRESSION", JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, NEW YORK, NY, US, vol. 59, no. 4, April 2000 (2000-04-01), pages 314 - 322, XP009037740, ISSN: 0022-3069 *
MINORETTI ET AL: "Effect of the functional toll-like receptor 4 Asp299Gly polymorphism on susceptibility to late-onset Alzheimer's disease", NEUROSCIENCE LETTERS, LIMERICK, IE, vol. 391, no. 3, 2 January 2006 (2006-01-02), pages 147 - 149, XP005191966, ISSN: 0304-3940 *
TAKAHASHI NOBUYUKI ET AL: "Two novel spliced presenilin 2 transcripts in human lymphocyte with oxidant stress and brain.", MOLECULAR AND CELLULAR BIOCHEMISTRY, vol. 252, no. 1-2, October 2003 (2003-10-01), pages 279 - 283, XP002411664, ISSN: 0300-8177 *
WU YING-HUI ET AL: "Pineal clock gene oscillation is disturbed in Alzheimer's disease, due to functional disconnection from the "master clock".", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY SEP 2006, vol. 20, no. 11, September 2006 (2006-09-01), pages 1874 - 1876, XP002460022, ISSN: 1530-6860 *

Also Published As

Publication number Publication date
US20100055682A1 (en) 2010-03-04
CN101490280A (zh) 2009-07-22
EP2021509A2 (fr) 2009-02-11
IL195288A (en) 2013-10-31
FR2900936A1 (fr) 2007-11-16
AU2007251408B2 (en) 2012-11-29
FR2980484A1 (fr) 2013-03-29
CN101490280B (zh) 2012-09-26
CA2652258A1 (fr) 2007-11-22
IL195288A0 (en) 2009-08-03
WO2007132120A2 (fr) 2007-11-22
JP2009537133A (ja) 2009-10-29
ZA200810528B (en) 2009-10-28
KR20090098941A (ko) 2009-09-18
NZ573505A (en) 2011-04-29
FR2900936B1 (fr) 2013-01-04
AU2007251408A1 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2007132120A3 (fr) Procede et methodes de detection de la maladie d'alzheimer
WO2009144424A3 (fr) Procede et methodes de diagnostic de la maladie d'alzheimer
WO2007114947A3 (fr) Système et procédés hautement sensibles destinés à une analyse de la troponine
WO2008021290A8 (fr) Protéines spécifiques d'organes et procédés d'utilisation
WO2007048978A3 (fr) Procede de detection du cancer
WO2002086448A3 (fr) Detection de l'instabilite des microsatellites et son utilisation dans le diagnostic des tumeurs
WO2009058902A3 (fr) Procédés et dispositifs pour une détection d'analyte
WO2006122311A3 (fr) Puce microfluidique
WO2009048530A3 (fr) Dosages à base de particules hautement multiplexées
WO2006020269A3 (fr) Biomarqueurs de maladie neurodegenerative
WO2005044990A3 (fr) Sequences d'acide nucleique differemment exprimees utilisees comme biomarqueurs du cancer
WO2007114986A3 (fr) Sondes coopératives et leurs procédés d'utilisation
WO2007018843A3 (fr) Methodes et compositions de diagnostic et de traitement de la grippe
WO2008082713A3 (fr) Matrice biologique à semi-conducteurs intégrés
WO2008033427A3 (fr) Compositions et procédés de détection d'une maladie lysosomale
WO2006090389A3 (fr) Nouveaux marqueurs diagnostiques, en particulier pour l'imagerie in vivo, et dosage et procedes d'utilisation associes
WO2008020823A3 (fr) Systèmes de rapporteur coopératifs, composants, et procédés pour une détection d'analyte
WO2009120183A3 (fr) Système pour la détection d’un pathogène biologique et utilisation de celui-ci
WO2009007649A3 (fr) Dispositif et procede d'identification et de determination de groupes sanguins
WO2007010379A3 (fr) Evaluation calorimetrique de micro-organismes et utilisation
WO2008103202A3 (fr) Protéines et gènes associés à l'hypoxie et permettant le diagnostic et le traitement des complications liées à la grossesse
WO2011012691A3 (fr) Processus et procédés de diagnostic de la maladie d'alzheimer
WO2007117330A3 (fr) Criblages de la protéine c latente et leurs usages pour le diagnostic et/ou le pronostic de syndromes de réponse inflammatoire systémique
WO2008149364A3 (fr) Procédés de diagnostic de réactions d'hypersensibilité
WO2006086377A3 (fr) Methode de detection de fievre porcine classique

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780026786.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07766039

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2652258

Country of ref document: CA

Ref document number: 2009510510

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 573505

Country of ref document: NZ

Ref document number: 2007251408

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007766039

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2649/MUMNP/2008

Country of ref document: IN

Ref document number: 1020087030380

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007251408

Country of ref document: AU

Date of ref document: 20070514

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12227374

Country of ref document: US